Linkedin
non-clinical-safety-solutions-logo

Due Diligence Reviews, Impurity Assessments & Safety Liability Identification

Overview

Successful drug development requires not only strong science but also an early understanding of the hidden risks that can influence investment decisions, partnership opportunities, and long-term development strategy. Nonclinical Safety Solutions (NCSS) provides independent, regulator-informed due diligence and impurity assessment services to help pharmaceutical and biotech organizations identify safety liabilities early, assess program risks objectively, and move forward with confidence.

With more than 25 years of industry experience—and a background as a former FDA Pharmacology/Toxicology reviewer—Dr. Thomas D. Steele brings rare insight into the scientific, regulatory, and strategic factors that determine whether a development program is positioned for success. NCSS evaluates your data packages, study designs, impurity profiles, and safety findings with the same rigor applied during regulatory review, giving you a clear and unbiased understanding of strengths, gaps, and potential barriers.

Whether you are investing in a new asset, preparing a program for partnership, addressing impurity-related concerns, or navigating the complexities of evolving ICH expectations, NCSS provides the clarity and expertise needed to assess risk, strengthen scientific justification, and reduce downstream surprises.

Core Services Included in Due Diligence & Impurity Evaluation

Scientific Due Diligence for Development Programs

  • Independent evaluation of nonclinical data packages
  • Identification of safety liabilities and key program risks
  • Assessment of regulatory readiness and data completeness
  • Recommendations for risk mitigation, study additions, or strategic repositioning

Impurity Safety Assessments

  • Evaluation of process-related impurities, degradants, and metabolites
  • Alignment with global regulatory frameworks including ICH M7, ICH Q3A/Q3B, and related guidance
  • Determination of qualification thresholds and supporting data requirements
  • Scientific justification for Acceptable Daily Intake (ADI) or TTC-based impurity limits

Regulatory-Aligned Gap Analysis

  • Review of pivotal studies, endpoints, and program structure
  • Identification of missing data likely to trigger regulatory questions or delays
  • Strategic planning to address gaps efficiently and cost-effectively

Risk Communication & Safety Narrative Development

  • Clear, decision-enabling risk summaries for internal stakeholders or investors
  • Safety justification documents to support partnership discussions or acquisitions
  • Integration of toxicology, PK/ADME, and impurity data into a coherent, regulator-ready risk profile

Mechanistic Reasoning & Follow-Up Planning

  • Evaluation of potential mechanisms behind concerning findings
  • Guidance on targeted follow-up studies to reduce uncertainty
  • Recommendations for impurity qualification strategies or alternative approaches

Why This Service Matters

Asset valuation, investment decisions, and regulatory outcomes all depend on a thorough understanding of safety risks—yet many programs progress with gaps or unrecognized liabilities that only surface once regulators scrutinize the data. NCSS provides the unbiased, scientifically grounded evaluation needed to identify these issues early and prevent costly setbacks.

Dr. Steele’s combined experience across industry leadership, study execution, and internal FDA review offers clients a uniquely comprehensive perspective. NCSS translates complex findings into actionable insights, strengthens safety narratives, and helps teams build development strategies that withstand rigorous scientific and regulatory evaluation.

Whether you are acquiring a molecule, preparing for a financing round, or ensuring your impurity control strategy aligns with global expectations, NCSS delivers the clarity, scientific rigor, and regulatory insight required to move forward confidently. To discuss a specific program or asset, request a consultation with NCSS.

Frequently Asked Questions

1. What is included in a nonclinical due diligence review?

A due diligence review assesses toxicology, PK/ADME, pharmacology, study design, regulatory gaps, safety signals, impurity profiles, and overall readiness for partnership, milestones, or investment decisions.

2. Why are impurity evaluations important in drug development?

Regulators require a clear understanding of process-related impurities and degradants, including their toxicological relevance and qualification thresholds, to ensure patient safety and product quality.

3. What is ICH M7 and how does it apply to impurities?

ICH M7 provides guidance for assessing and controlling DNA-reactive (mutagenic) impurities to limit potential carcinogenic risk. NCSS helps interpret and apply this framework to real-world impurity profiles.

4. Can NCSS assist with evaluating an asset before acquisition or licensing?

Yes. NCSS frequently provides independent due diligence assessments to support investment decisions, identify hidden risks, and strengthen the scientific narrative for negotiations.

5. How early should impurity evaluations begin?

Impurity assessments should begin as soon as process chemistry or stability studies reveal potential degradants—well before regulatory submission—to avoid delays or unexpected qualification studies.

6. Can NCSS help develop a plan to qualify impurities?

Absolutely. NCSS evaluates available data, determines what additional studies may be required, and provides a regulatory-aligned strategy for impurity qualification and risk mitigation.

Expertise

Contact Us

To learn how NCSS can support your nonclinical and regulatory strategy, request a consultation